Hansoh Pharmaceutical Group Co Ltd

Goldman Sachs has identified Chinese healthcare stocks as a key post-AI growth opportunity, with pharmaceutical names accounting for one-third of the 12 companies that made its final screen. In a Sept. 7 report, the firm's portfolio strategy research team said nearly half of MSCI China index constituents beat estimates in the second quarter, led by IT and healthcare, and that Chinese stocks' earnings tracked by Goldman Sachs grew at their highest quarterly pace in five years at 24% in the second quarter from a year ago, accelerating from just 6% in the first quarter. The analysts screened their buy-rated coverage for Chinese companies with expected earnings growth of more than 15% annually through 2027 and an increase in earnings per share estimates by a median of 7% over the past month. The four healthcare names on the list are Suzhou-based Innovent Biologics, whose earnings are expected to more than double in the year ahead with Goldman's estimate 54 percentage points above consensus; Shanghai-listed BeOne Medicines, also expected to more than double; Hong Kong-listed CSPC, forecast to grow 26%; and Hong Kong-listed Hansoh Pharma, forecast to grow 15%. Goldman expects MSCI China earnings to grow by 8% this year, far more conservative than the consensus forecast for 17%.

On the morning of July 15, the three major A-share indexes gave up early gains. By the midday break, the Shanghai Composite Index was down 0.08%, the Shenzhen Component Index down 0.38%, the ChiNext Index down 0.36%, and the STAR Composite Index down 2.72%. The pharmaceutical sector saw a broad rally, with GemPharmatech, ChemPartner, BrightGene Bio-Medical Technology, and Dizal Pharmaceutical all surging by the 20% daily limit. Over ten other stocks, including Joinn Laboratories, Haisco Pharmaceutical, and Baihua Pharmaceutical, also hit their daily limit. Harbin Pharmaceutical Group locked in its fourth consecutive daily limit. Baijiu stocks were all in positive territory, with Golden Seed Winery hitting the daily limit. Kweichow Moutai rose over 2%, Wuliangye Yibin over 3%, Shanxi Xinghuacun Fen Wine Factory over 6%, and Luzhou Laojiao nearly 6%. The semiconductor sector fell sharply, with Demingli hitting the daily limit down. Precious metals and communication equipment sectors were among the biggest decliners. In news, the National Healthcare Security Administration released the list of drugs that passed the formal review for the 2026 drug catalog adjustment. Meanwhile, the internationalization of Chinese innovative drugs is accelerating. Three outbound licensing deals by Dizal Pharmaceutical, Hansoh Pharmaceutical, and Innovent Biologics each reached several billion US dollars in total value. In the first half of 2026, the total value of Chinese pharmaceutical outbound deals reached 99.7 billion US dollars, already exceeding the full-year figure for 2024.

Hansoh Pharmaceutical Group announced positive Phase III results for its investigational therapy Ris-Rez in small-cell lung cancer. The ARTEMIS-008 trial met its primary endpoint, demonstrating statistically significant and clinically meaningful overall survival improvement versus topotecan. Consistent benefits were also seen in secondary endpoints including progression-free survival, with a safety profile consistent with earlier studies and no new safety signals. These are the first pivotal Phase III overall survival data for a B7-H3-targeted antibody-drug conjugate in any tumor type. GSK holds exclusive global rights to Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan, and is advancing a broad clinical program with pivotal global Phase III data expected next year.